EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP

FEBS Letters

Volumn 584, Issue 19, 2010, Pages 4259-4267

  Fernandez, Jamie Winderbaum ^a,b   Rezai Zadeh, Kavon ^c   Obregon, Demian ^a,b   Tan, Jun ^a,b  

^a Silver Child Development Center   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

A disintegrin and metalloprotease domain 10; Alzheimer's disease; Amyloid precursor protein; Epigallocatechin gallate; Estrogen; Furin; Phosphoinositide 3 kinase

Indexed keywords

ADAM10 ENDOPEPTIDASE; ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; EPIGALLOCATECHIN GALLATE; ESTROGEN RECEPTOR ALPHA; FURIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME ACTIVATION; HORMONE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION;

ADAM PROTEINS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CATECHIN; CELL LINE; DISEASE MODELS, ANIMAL; ESTROGEN RECEPTOR ALPHA; FEMALE; FURIN; HUMANS; MEMBRANE PROTEINS; MICE; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

MUS;

EID: 77957128191     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.09.022     Document Type: Article

References (74)

1. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
2. Jorissen E., et al. The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J. Neurosci. 2010, 30:4833-4844.
3. Postina R., et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 2004, 113:1456-1464.
4. Fahrenholz F. Alpha-secretase as a therapeutic target. Curr. Alzheimer Res. 2007, 4:412-417.
5. Fahrenholz F., Tippmann F., Endres K. Retinoids as a perspective in treatment of Alzheimer's disease. Neurodegener Dis. 2010, 7:190-192.
6. Lannfelt L., Basun H., Vigo-Pelfrey C., Wahlund L.O., Winblad B., Lieberburg I., Schenk D. Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. Neurosci. Lett. 1995, 199:203-206.
7. Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C., Fahrenholz F. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. USA 1999, 96:3922-3927.
8. Gandhi S., Refolo L.M., Sambamurti K. Amyloid precursor protein compartmentalization restricts beta-amyloid production: therapeutic targets based on BACE compartmentalization. J. Mol. Neurosci. 2004, 24:137-143.
9. Baum L.W. Sex, hormones, and Alzheimer's disease. J. Gerontol. A Biol. Sci. Med. Sci. 2005, 60:736-743.
10. Musicco M. Gender differences in the occurrence of Alzheimer's disease. Funct. Neurol. 2009, 24:89-92.
11. Rosario, E.R., Chang, L., Head, E.H., Stanczyk, F.Z. and Pike, C.J. (2009). Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease. Neurobiol. Aging.
12. Jaffe A.B., Toran-Allerand C.D., Greengard P., Gandy S.E. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J. Biol. Chem. 1994, 269:13065-13068.
13. Xu H., et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat. Med. 1998, 4:447-451.
14. Carroll J.C., Pike C.J. Selective estrogen receptor modulators differentially regulate Alzheimer-like changes in female 3×Tg-AD mice. Endocrinology 2008, 149:2607-2611.
15. Carroll J.C., Rosario E.R., Chang L., Stanczyk F.Z., Oddo S., LaFerla F.M., Pike C.J. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J. Neurosci. 2007, 27:13357-13365.
16. Honjo H., et al. Progestins and estrogens and Alzheimer's disease. J. Steroid Biochem. Mol. Biol. 2005, 93:305-308.
17. Almeida O.P., Flicker L. Association between hormone replacement therapy and dementia: is it time to forget?. Int. Psychogeriatr. 2005, 17:155-164.
18. Tang M.X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H., Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996, 348:429-432.
19. Sano M., et al. A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics. Clin. Trials 2008, 5:523-533.
20. Gandy S. Neurohormonal signaling pathways and the regulation of Alzheimer beta-amyloid precursor metabolism. Trends Endocrinol. Metab. 1999, 10:273-279.
21. Gandy S., Petanceska S. Regulation of Alzheimer beta-amyloid precursor trafficking and metabolism. Biochim. Biophys. Acta 2000, 1502:44-52.
22. Pike C.J., Carroll J.C., Rosario E.R., Barron A.M. Protective actions of sex steroid hormones in Alzheimer's disease. Front. Neuroendocrinol. 2009, 30:239-258.
23. Moyers S.B., Kumar N.B. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr. Rev. 2004, 62:204-211.
24. Lin J.K., Liang Y.C. Cancer chemoprevention by tea polyphenols. Proc. Natl Sci. Counc. Repub. China B 2000, 24:1-13.
25. Fang H., et al. Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chem. Res. Toxicol. 2001, 14:280-294.
26. Park J.W., Choi Y.J., Suh S.I., Kwon T.K. Involvement of ERK and protein tyrosine phosphatase signaling pathways in EGCG-induced cyclooxygenase-2 expression in Raw 264.7 cells. Biochem. Biophys. Res. Commun. 2001, 286:721-725.
27. Okamoto M., Leung K.P., Ansai T., Sugimoto A., Maeda N. Inhibitory effects of green tea catechins on protein tyrosine phosphatase in Prevotella intermedia. Oral Microbiol. Immunol. 2003, 18:192-195.
28. Levites Y., Amit T., Mandel S., Youdim M.B. Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J. 2003, 17:952-954.
29. Levites Y., Amit T., Youdim M.B., Mandel S. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J. Biol. Chem. 2002, 277:30574-30580.
30. Li R., Huang Y.G., Fang D., Le W.D. (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. J. Neurosci. Res. 2004, 78:723-731.
31. Han M.K. Epigallocatechin gallate, a constituent of green tea, suppresses cytokine-induced pancreatic beta-cell damage. Exp. Mol. Med. 2003, 35:136-139.
32. Ahmed S., Rahman A., Hasnain A., Lalonde M., Goldberg V.M., Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic. Biol. Med. 2002, 33:1097-1105.
33. Aktas O., et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 2004, 173:5794-5800.
34. Lin C.L., Chen T.F., Chiu M.J., Way T.D., Lin J.K. Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation. Neurobiol. Aging 2009, 30:81-92.
35. Chung J.H., Han J.H., Hwang E.J., Seo J.Y., Cho K.H., Kim K.H., Youn J.I., Eun H.C. Dual mechanisms of green tea extract (EGCG)-induced cell survival in human epidermal keratinocytes. FASEB J. 2003, 17:1913-1915.
36. Rezai-Zadeh K., et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 2005, 25:8807-8814.
37. Obregon D.F., et al. ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 2006, 281:16419-16427.
38. Tan J., et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat. Neurosci. 2002, 5:1288-1293.
39. Chen M., Fernandez H.L. Stimulation of beta-amyloid precursor protein alpha-processing by phorbol ester involves calcium and calpain activation. Biochem. Biophys. Res. Commun. 2004, 316:332-340.
40. Manthey D., Heck S., Engert S., Behl C. Estrogen induces a rapid secretion of amyloid beta precursor protein via the mitogen-activated protein kinase pathway. Eur. J. Biochem. 2001, 268:4285-4291.
41. Gouras G.K., Xu H., Gross R.S., Greenfield J.P., Hai B., Wang R., Greengard P. Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. Proc. Natl. Acad. Sci. USA 2000, 97:1202-1205.
42. Goodin M.G., Fertuck K.C., Zacharewski T.R., Rosengren R.J. Estrogen receptor-mediated actions of polyphenolic catechins in vivo and in vitro. Toxicol. Sci. 2002, 69:354-361.
43. Qiao Y., Cao J., Xie L., Shi X. Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells. Arch. Pharm. Res. 2009, 32:1309-1315.
44. Mendez P., Garcia-Segura L.M. Phosphatidylinositol 3-kinase and glycogen synthase kinase 3 regulate estrogen receptor-mediated transcription in neuronal cells. Endocrinology 2006, 147:3027-3039.
45. Sun J., Huang Y.R., Harrington W.R., Sheng S., Katzenellenbogen J.A., Katzenellenbogen B.S. Antagonists selective for estrogen receptor alpha. Endocrinology 2002, 143:941-947.
46. Yi K.W., et al. Role of estrogen receptor-alpha and -beta in regulating leptin expression in 3T3-L1 adipocytes. Obesity (Silver Spring) 2008, 16:2393-2399.
47. Lorenz M., Wessler S., Follmann E., Michaelis W., Dusterhoft T., Baumann G., Stangl K., Stangl V. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J. Biol. Chem. 2004, 279:6190-6195.
48. Petanceska S.S., Gandy S. The phosphatidylinositol 3-kinase inhibitor wortmannin alters the metabolism of the Alzheimer's amyloid precursor protein. J. Neurochem. 1999, 73:2316-2320.
49. Cali, J.J. (2001) Frequently asked questions: kinase inhibitors and activators. Cell Notes (Promega Corp.).
50. Anders A., Gilbert S., Garten W., Postina R., Fahrenholz F. Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein convertases. FASEB J. 2001, 15:1837-1839.
51. Anderson E.D., Molloy S.S., Jean F., Fei H., Shimamura S., Thomas G. The ordered and compartment-specfific autoproteolytic removal of the furin intramolecular chaperone is required for enzyme activation. J. Biol. Chem. 2002, 277:12879-12890.
52. De Strooper B., Vassar R., Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:99-107.
53. Chow H.H., et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin. Cancer Res. 2003, 9:3312-3319.
54. Kuruto-Niwa R., Inoue S., Ogawa S., Muramatsu M., Nozawa R. Effects of tea catechins on the ERE-regulated estrogenic activity. J. Agric. Food. Chem. 2000, 48:6355-6361.
55. Farabegoli F., Barbi C., Lambertini E., Piva R. (-)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detect. Prev. 2007, 31:499-504.
56. Barnes L.L., Wilson R.S., Bienias J.L., Schneider J.A., Evans D.A., Bennett D.A. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch. Gen. Psychiatry 2005, 62:685-691.
57. Ruitenberg A., Ott A., van Swieten J.C., Hofman A., Breteler M.M. Incidence of dementia: does gender make a difference?. Neurobiol. Aging 2001, 22:575-580.
58. Swanwick G., Lawlor B.A. Is female gender a risk factor for Alzheimer's disease?. Int. Psychogeriatr. 1999, 11:219-222.
59. Schupf N., et al. Estrogen receptor-alpha variants increase risk of Alzheimer's disease in women with down syndrome. Dement. Geriatr. Cogn. Disord. 2008, 25:476-482.
60. Porrello E., Monti M.C., Sinforiani E., Cairati M., Guaita A., Montomoli C., Govoni S., Racchi M. Estrogen receptor alpha and APOEepsilon4 polymorphisms interact to increase risk for sporadic AD in Italian females. Eur. J. Neurol. 2006, 13:639-644.
61. Mattila K.M., et al. Interaction between estrogen receptor 1 and the epsilon4 allele of apolipoprotein E increases the risk of familial Alzheimer's disease in women. Neurosci. Lett. 2000, 282:45-48.
62. Ma S.L., Tang N.L., Tam C.W., Lui V.W., Lau E.S., Zhang Y.P., Chiu H.F., Lam L.C. Polymorphisms of the estrogen receptor alpha (ESR1) gene and the risk of Alzheimer's disease in a southern Chinese community. Int. Psychogeriatr. 2009, 21:977-986.
63. Corbo R.M., Gambina G., Ruggeri M., Scacchi R. Association of estrogen receptor alpha (ESR1) PvuII and XbaI polymorphisms with sporadic Alzheimer's disease and their effect on apolipoprotein E concentrations. Dement. Geriatr. Cogn. Disord. 2006, 22:67-72.
64. Rezai-Zadeh K., et al. Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production. J. Cell. Mol. Med. 2009, 13:574-588.
65. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J. Alzheimers Dis. 2006, 9:309-317.
66. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423:435-439.
67. Yi K.D., Cai Z.Y., Covey D.F., Simpkins J.W. Estrogen receptor-independent neuroprotection via protein phosphatase preservation and attenuation of persistent extracellular signal-regulated kinase 1/2 activation. J. Pharmacol. Exp. Ther. 2008, 324:1188-1195.
68. Quesada A., Lee B.Y., Micevych P.E. PI3Kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev. Neurobiol. 2008, 68:632-644.
69. Mannella P., Brinton R.D. Estrogen receptor protein interaction with phosphatidylinositol 3-kinase leads to activation of phosphorylated Akt and extracellular signal-regulated kinase 1/2 in the same population of cortical neurons: a unified mechanism of estrogen action. J. Neurosci. 2006, 26:9439-9447.
70. Zhao L., Brinton R.D. Estrogen receptor alpha and beta differentially regulate intracellular Ca(2+) dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons. Brain Res. 2007, 1172:48-59.
71. Janes P.W., et al. Cytoplasmic relaxation of active Eph controls ephrin shedding by ADAM10. PLoS Biol. 2009, 7:e1000215.
72. Zhou A., Martin S., Lipkind G., LaMendola J., Steiner D.F. Regulatory roles of the P domain of the subtilisin-like prohormone convertases. J. Biol. Chem. 1998, 273:11107-11114.
73. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol. 2002, 3:753-766.
74. Tarr P.E., Roncarati R., Pelicci G., Pelicci P.G., D'Adamio L. Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc. J. Biol. Chem. 2002, 277:16798-16804.